Literature DB >> 1979140

Human T-lymphotropic virus type I screening in volunteer blood donors--United States, 1989.

.   

Abstract

On November 29, 19898, the Food and Drug Administration (FDA) issued recommendations to screen all whole blood donations in the United States for human T-lymphotropic virus type I (HTLV-1). This report summarizes results of the first 13 months of screening (December 1988 through December 1989) by the American Red Cross (ARC) and the Council of Community Blood Centers (CCBC).

Entities:  

Mesh:

Year:  1990        PMID: 1979140

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  5 in total

Review 1.  Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases.

Authors:  Denise Utsch Gonçalves; Fernando Augusto Proietti; João Gabriel Ramos Ribas; Marcelo Grossi Araújo; Sônia Regina Pinheiro; Antônio Carlos Guedes; Anna Bárbara F Carneiro-Proietti
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

2.  Phenotypic expression of integrin membrane receptors on spontaneously proliferating CD8 cells in human T-lymphotropic virus type II (HTLV-II)-infected individuals.

Authors:  R B Lal; D L Rudolph; T Rowe; T M Folks
Journal:  J Clin Immunol       Date:  1992-03       Impact factor: 8.317

3.  Isolation, characterization, and transmission of human T-lymphotropic virus types I and II in culture.

Authors:  K Kitamura; D L Rudolph; C Goldsmith; T M Folks; R B Lal
Journal:  Curr Microbiol       Date:  1993-12       Impact factor: 2.188

Review 4.  Viral Oncology: Molecular Biology and Pathogenesis.

Authors:  Uyen Ngoc Mui; Christopher T Haley; Stephen K Tyring
Journal:  J Clin Med       Date:  2017-11-29       Impact factor: 4.241

5.  Human T-Cell Lymphotropic Virus Types 1 and 2 Seropositivity among Blood Donors at Mbarara Regional Blood Bank, South Western Uganda.

Authors:  Patience Uchenna Tweteise; Bernard Natukunda; Joel Bazira
Journal:  Leuk Res Treatment       Date:  2016-02-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.